Literature DB >> 3207699

Kinetic properties of the binding of alpha-lytic protease to peptide boronic acids.

C A Kettner1, R Bone, D A Agard, W W Bachovchin.   

Abstract

The kinetic parameters for peptide boronic acids in their interaction with alpha-lytic protease were determined and found to be similar to those of other serine proteases [Kettner, C., & Shenvi, A. B. (1984) J. Biol. Chem. 259, 15106-15114]. alpha-Lytic protease hydrolyzes substrates with either alanine or valine in the P1 site and has a preference for substrate with a P1 alanine. The most effective inhibitors are tri- and tetrapeptide analogues that have a -boroVal-OH residue in the P1 site. At pH 7.5, MeOSuc-Ala-Ala-Pro-boroVal-OH has a Ki of 6.4 nM and Boc-Ala-Pro-boroVal-OH has a Ki of 0.35 nM. Ac-boroVal-OH and Ac-Pro-boroVal-OH are 220,000- and 500-fold less effective, respectively, than the tetrapeptide analogue. The kinetic properties of the tri- and tetrapeptide analogues are consistent with the mechanism for slow-binding inhibition, E + I in equilibrium EI in equilibrium EI*, while the less effective inhibitors are simple competitive inhibitors. MeO-Suc-Ala-Ala-Pro-boroAla-OH is a simple competitive inhibitor with a Ki of 67 nM at pH 7.5. Other peptide boronic acids, which are analogues of nonsubstrates, are less effective than substrate analogues but still are effective competitive inhibitors. For example, MeOSuc-Ala-Ala-Pro-boroPhe-OH has a Ki of 0.54 microM although substrates with a phenylalanine in the P1 position are not hydrolyzed. Binding for boronic acid analogues of both substrate and nonsubstrate analogues is pH dependent with higher affinity near pH 7.5. Similar binding properties have been observed for pancreatic elastase. Both enzymes have almost identical requirements for an extended peptide inhibitor sequence in order to exhibit highly effective binding and slow-binding characteristics.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3207699     DOI: 10.1021/bi00420a017

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Conformational substates in enzyme mechanism: the 120 K structure of alpha-lytic protease at 1.5 A resolution.

Authors:  S D Rader; D A Agard
Journal:  Protein Sci       Date:  1997-07       Impact factor: 6.725

2.  Crystal versus solution structure of enzymes: NMR spectroscopy of a peptide boronic acid-serine protease complex in the crystalline state.

Authors:  S Farr-Jones; S O Smith; C A Kettner; R G Griffin; W W Bachovchin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function.

Authors:  G R Flentke; E Munoz; B T Huber; A G Plaut; C A Kettner; W W Bachovchin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

4.  Unusual 1H NMR chemical shifts support (His) C(epsilon) 1...O==C H-bond: proposal for reaction-driven ring flip mechanism in serine protease catalysis.

Authors:  E L Ash; J L Sudmeier; R M Day; M Vincent; E V Torchilin; K C Haddad; E M Bradshaw; D G Sanford; W W Bachovchin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

5.  Heparin enhances the catalytic activity of des-ETW-thrombin.

Authors:  C A Goodwin; J J Deadman; B F Le Bonniec; S Elgendy; V V Kakkar; M F Scully
Journal:  Biochem J       Date:  1996-04-01       Impact factor: 3.857

6.  Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells.

Authors:  R C Gardner; S J Assinder; G Christie; G G Mason; R Markwell; H Wadsworth; M McLaughlin; R King; M C Chabot-Fletcher; J J Breton; D Allsop; A J Rivett
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

7.  Alterations in chemical shifts and exchange broadening upon peptide boronic acid inhibitor binding to alpha-lytic protease.

Authors:  J H Davis; D A Agard; T M Handel; V J Basus
Journal:  J Biomol NMR       Date:  1997-07       Impact factor: 2.835

8.  Involvement of dipeptidyl peptidase IV in an in vivo immune response.

Authors:  T Kubota; G R Flentke; W W Bachovchin; B D Stollar
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

9.  Inhibition of chymotrypsin by a complex of ortho-vanadate and benzohydroxamic acid: structure of the inert complex and its mechanistic interpretation.

Authors:  Aaron Moulin; Jason H Bell; R F Pratt; Dagmar Ringe
Journal:  Biochemistry       Date:  2007-05-01       Impact factor: 3.162

10.  Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset.

Authors:  T Kubota; H Iizuka; W W Bachovchin; B D Stollar
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.